Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) shares shot up 9.8% during trading on Wednesday . The stock traded as high as $13.90 and last traded at $13.86. 39,270 shares were traded during mid-day trading, a decline of 80% from the average session volume of 192,962 shares. The stock had previously closed at $12.62.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on RAPP. JMP Securities reissued a "market outperform" rating and issued a $28.00 price target on shares of Rapport Therapeutics in a report on Tuesday. Citizens Jmp initiated coverage on Rapport Therapeutics in a research note on Tuesday, April 8th. They issued a "mkt outperform" rating for the company.
Check Out Our Latest Stock Analysis on Rapport Therapeutics
Rapport Therapeutics Trading Up 2.8%
The stock has a market capitalization of $525.45 million and a PE ratio of -4.18. The firm has a 50 day moving average of $11.11 and a two-hundred day moving average of $12.17.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.09. Equities research analysts forecast that Rapport Therapeutics, Inc. will post -3.65 EPS for the current year.
Hedge Funds Weigh In On Rapport Therapeutics
Several hedge funds have recently bought and sold shares of RAPP. Legal & General Group Plc grew its position in shares of Rapport Therapeutics by 947.6% in the fourth quarter. Legal & General Group Plc now owns 9,523 shares of the company's stock valued at $169,000 after purchasing an additional 8,614 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Rapport Therapeutics in the fourth quarter valued at $34,000. GAMMA Investing LLC boosted its holdings in Rapport Therapeutics by 91,980.0% in the first quarter. GAMMA Investing LLC now owns 9,208 shares of the company's stock valued at $918,000 after acquiring an additional 9,198 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Rapport Therapeutics by 1,151.2% in the fourth quarter. California State Teachers Retirement System now owns 8,571 shares of the company's stock valued at $152,000 after acquiring an additional 7,886 shares during the last quarter. Finally, Barclays PLC boosted its holdings in Rapport Therapeutics by 43.8% in the fourth quarter. Barclays PLC now owns 18,497 shares of the company's stock valued at $328,000 after acquiring an additional 5,634 shares during the last quarter.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Further Reading
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
